COLOMBO NICOLETTA

Harano, K., Fossati, R., Pardo, B., Galli, F., Hudson, E., Antill, Y., et al. (2025). Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial. JOURNAL OF GYNECOLOGIC ONCOLOGY, 36(4) [10.3802/jgo.2025.36.e117]. Detail

Kim, Y., Nishio, S., Kim, S., Hasegawa, K., Dubot, C., Valeria Cáceres, M., et al. (2025). Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis. JOURNAL OF GYNECOLOGIC ONCOLOGY, 36(4) [10.3802/jgo.2025.36.e110]. Detail

Scambia, G., Villalobos Valencia, R., Colombo, N., Cibula, D., Leath, C., Bidzinski, M., et al. (2025). Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results. JOURNAL OF CLINICAL ONCOLOGY, 43(12), 1408-1416 [10.1200/JCO.24.00933]. Detail

Ledermann, J., Oza, A., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., et al. (2025). Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial. EUROPEAN JOURNAL OF CANCER, 225 [10.1016/j.ejca.2025.115584]. Detail

Lorusso, D., Xiang, Y., Hasegawa, K., Scambia, G., Leiva, M., Ramos-Elias, P., et al. (2025). Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): Overall Survival Results From a Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial. OBSTETRICAL & GYNECOLOGICAL SURVEY, 80(2), 93-95 [10.1097/01.ogx.0001108096.71273.16]. Detail